mdlinx mdlinx
Latest (109) Full Text Articles (3243) Focus on Arrhythmias Article Summary

On-treatment non–high-density lipoprotein cholesterol, apolipoprotein b, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy Full Text
JACC - Journal of the American College of Cardiology,  Clinical Article

Mora S et al. – In this primary prevention trial of nondiabetic individuals with low LDL–C and elevated high–sensitivity C–reactive protein, on–treatment LDL–C was as valuable as non–HDL–C, apolipoprotein B, or ratios in predicting residual risk.

Methods
  • Participants in the randomized placebo–controlled JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial were adults without diabetes or CVD, with baseline LDL–C levels <130 mg/dl, high–sensitivity C–reactive protein levels 2 mg/l, and triglyceride concentrations <500 mg/dl.
  • Individuals allocated to receive rosuvastatin 20 mg daily with baseline and on–treatment lipids and lipoproteins were examined in relation to the primary endpoint of incident CVD (nonfatal myocardial infarction or stroke, hospitalization for unstable angina, arterial revascularization, or cardiovascular death).

Results
  • Using separate multivariate Cox models, statistically significant associations of a similar magnitude with residual risk of CVD were found for on–treatment LDL–C, non–HDL–C, apolipoprotein B, total cholesterol/HDL–C, LDL–C/HDL–C, and apolipoprotein B/A–I.
  • The respective adjusted standardized hazard ratios (95% confidence intervals) for each of these measures were 1.31 (1.09 to 1.56), 1.25 (1.04 to 1.50), 1.27 (1.06 to 1.53), 1.22 (1.03 to 1.44), 1.29 (1.09 to 1.52), and 1.27 (1.09 to 1.49).
  • The overall residual risk and the risk associated with these measures decreased among participants achieving on–treatment LDL–C 70 mg/dl, on–treatment non–HDL–C 100 mg/dl, or on–treatment apolipoprotein B 80 mg/dl.
  • In contrast, on–treatment triglycerides showed no association with CVD.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

Last month's top read Top Articles of 2013

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Other Topics in Cardiology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close